UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to s Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdiction ...

Exhibit 99.1 CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., August 12, 2025 ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdiction ...

[CalciMedica First Quarter 2025 Financial Results and Corporate Updates](index=1&type=section&id=CalciMedica%20Reports%20First%20Quarter%202025%20Financial%20Results%20and%20Provides%20Clinical%20%26%20Corporate%20Updates) [Recent Clinical & Corporate Highlights](index=1&type=section&id=Recent%20Clinical%20%26%20Corporate%20Highlights) CalciMedica advances its AKI program with ongoing KOURAGE trial enrollment and positive Auxora data, while securing new financing and strengthening its board - Enrollment is ongoing in the Phase 2 KOURAGE trial for Auxora™ in acute kidney injury (AKI), with data expected around the end of 2025[1](index=1&type=chunk)[4](index=4&type=chunk) - A post-hoc analysis of the Phase 2 CARDEA trial in a subset of patients with AKI showed a **62.7% relative reduction in mortality** for those treated with Auxora compared to placebo[1](index=1&type=chunk)[5](index=5&type=chunk) - The company's cash position is expected to fund operations into mid-2026, supported by a new credit facility of up to **$32.5 million**[1](index=1&type=chunk)[3](index=3&type=chunk)[8](index=8&type=chunk) [Acute Kidney Injury (AKI) Program Update](index=1&type=section&id=Acute%20Kidney%20Injury%20%28AKI%29%20Program%20Update) The AKI program advances with the Phase 2 KOURAGE trial, expecting data by year-end 2025, supported by positive post-hoc CARDEA analysis demonstrating Auxora's mortality reduction - Enrollment is ongoing in the KOURAGE Phase 2 trial, which will enroll 150 patients with Stage 2 or 3 AKI and acute hypoxemic respiratory failure (AHRF) Data is anticipated around the end of 2025[4](index=4&type=chunk) - A post-hoc analysis of the CARDEA trial showed that in a subset of 38 patients with AKI, Auxora treatment led to a **62.7% relative reduction in mortality** versus placebo at day 30[5](index=5&type=chunk) - Mortality rates in the CARDEA post-hoc analysis were **17.4%** (4 out of 23) for the Auxora group, compared to **46.7%** (7 out of 15) for the placebo group at both day 30 and day 60[5](index=5&type=chunk) [Acute Pancreatitis (AP) Program Update](index=2&type=section&id=Acute%20Pancreatitis%20%28AP%29%20Program%20Update) CalciMedica plans an end-of-Phase 2 FDA meeting around mid-2025 for its AP program, aiming to initiate a Phase 3 trial by year-end, contingent on additional funding - An end-of-Phase 2 meeting with the U.S FDA is planned for around the middle of 2025[10](index=10&type=chunk) - The company anticipates being ready to start a Phase 3 program in AP with SIRS around the end of 2025, subject to additional funding[10](index=10&type=chunk) [Corporate Updates](index=2&type=section&id=Corporate%20Updates) CalciMedica strengthened its governance by appointing a new board member and enhanced financial flexibility by securing a credit facility of up to **$32.5 million** - In January 2025, Alan Glicklich, M.D., was appointed to the Company's Board of Directors[7](index=7&type=chunk) - On March 5, 2025, the company secured a credit facility providing up to **$32.5 million**, with an initial **$10 million** funded immediately[8](index=8&type=chunk) [Financial Results for the Three Months Ended March 31, 2025](index=2&type=section&id=Financial%20Results%20for%20the%20Three%20Months%20Ended%20March%2031%2C%202025) CalciMedica reported a **net loss of $5.9 million** for Q1 2025, driven by increased R&D expenses and decreased other income, ending the quarter with **$24.6 million** in cash - Cash, cash equivalents, and short-term investments totaled **$24.6 million** as of March 31, 2025, which is expected to fund operations into mid-2026[11](index=11&type=chunk) Q1 2025 vs Q1 2024 Financial Highlights | Financial Metric | Q1 2025 (in millions) | Q1 2024 (in millions) | Change (in millions) | | :--- | :--- | :--- | :--- | | R&D Expenses | $4.2 | $2.9 | +$1.3 | | G&A Expenses | $2.3 | $2.8 | -$0.5 | | Other Income | $1.5 | $5.9 | -$4.4 | | Net (Loss) Income | ($5.9) | $0.1 | -$6.0 | [Financial Statements](index=5&type=section&id=Financial%20Statements) Unaudited condensed consolidated financial statements show CalciMedica's total assets increased to **$25.3 million** due to a new promissory note, while total liabilities rose to **$14.5 million**, resulting in a **net loss of $5.0 million** for the quarter [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, CalciMedica's total assets increased to **$25.3 million**, driven by cash from a new promissory note, while total liabilities rose to **$14.5 million**, leading to a decrease in total stockholders' equity to **$10.9 million** Balance Sheet Summary (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total current assets** | **$25,218** | **$19,665** | | Cash and cash equivalents | $12,556 | $7,935 | | **Total assets** | **$25,347** | **$19,794** | | **Total current liabilities** | **$4,459** | **$3,684** | | Promissory note | $8,600 | $— | | **Total liabilities** | **$14,459** | **$5,384** | | **Total stockholders' equity** | **$10,888** | **$14,410** | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2025, the company reported total operating expenses of **$6.5 million**, resulting in a **net loss of $5.0 million**, or **($0.36)** per share, a significant downturn from the prior year's net income Statement of Operations Summary (in thousands, except per share data) | Account | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Research and development | $4,224 | $2,944 | | General and administrative | $2,273 | $2,823 | | **Total operating expenses** | **$6,497** | **$5,767** | | **Loss from operations** | **($6,497)** | **($5,767)** | | **Net (loss) income** | **($5,042)** | **$130** | | **Basic EPS** | **($0.36)** | **$0.01** | | **Diluted EPS** | **($0.36)** | **$0.01** |

Part I [Business](index=10&type=section&id=Item%201.%20Business) CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immunologic diseases by inhibiting calcium release-activated calcium (CRAC) channels [Overview and Pipeline](index=10&type=section&id=Item%201.%20Business-Overview%20and%20Pipeline) CalciMedica is a clinical-stage biopharmaceutical company developing a new class of drugs that inhibit CRAC channels to treat serious inflammatory and immunologic illnesses - The company focuses on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes, targeting **calcium release-activated calcium (CRAC) channels**[27](index=27&type=chunk) - The company's lead product candidate is **Auxora**, an intravenous (IV) small molecule CRAC channel inhibitor. It is currently in **Phase 2** trials for Acute Kidney Injury (AKI) with AHRF (KOURAGE) and a **Phase 1/2** trial for Asparaginase-Induced Pancreatic Toxicity (AIPT) (CRSPA)[29](index=29&type=chunk) Product Candidate Pipeline | Product Candidate | Indication | Stage of Development | | :--- | :--- | :--- | | **Auxora (IV)** | Acute Kidney Injury (AKI) with AHRF | Phase 2 (KOURAGE) | | **Auxora (IV)** | Acute Pancreatitis (AP) with SIRS | Phase 3 Planned | | **Auxora (IV)** | Asparaginase-Induced Pancreatic Toxicity (AIPT) | Phase 1/2 (CRSPA) | | **Oral CRACi** | Chronic Inflammatory & Immunologic Diseases | Preclinical | [Clinical Experience with Auxora](index=12&type=section&id=Item%201.%20Business-Clinical%20Experience%20with%20Auxora) Auxora has been studied in multiple Phase 2 trials across different acute critical care conditions, consistently showing a reduction in organ damage and time to recovery - In the CARDEA trial (COVID-19 Pneumonia), Auxora showed a statistically significant **56% relative reduction in mortality at 30 days** (p=0.016)[34](index=34&type=chunk) - In the CARPO trial (Acute Pancreatitis), the medium and high doses of Auxora demonstrated a **100% relative risk reduction in new-onset severe respiratory failure** compared to placebo (p=0.0027 for combined high/medium doses vs. combined placebo/low doses)[34](index=34&type=chunk)[43](index=43&type=chunk) Summary of Clinical Experience with Auxora | Trial | Indication | Phase | Year | Key Auxora Result | | :--- | :--- | :--- | :--- | :--- | | CARDEA | COVID-19 Pneumonia | 2 | 2021 | 56% reduction in mortality at 30 days | | CARPO | Acute Pancreatitis | 2b | 2024 | 100% reduction in new-onset severe respiratory failure (high/med dose) | | KOURAGE | Acute Kidney Injury | 2 | Ongoing (exp. 2025) | Primary Endpoint: Days ALIVE, not on VENTILATOR, not on DIALYSIS | [Our Science](index=18&type=section&id=Item%201.%20Business-Our%20Science) The company's scientific approach targets CRAC channels, which are crucial for calcium signaling in cells - **CRAC channels**, comprised of **STIM1** and **Orai1** proteins, are responsible for replenishing cellular calcium stores. In pathological conditions, their overactivation can lead to excessive calcium influx, causing cellular injury or death[51](index=51&type=chunk)[52](index=52&type=chunk) - The company's CRAC channel inhibitors provide a **dual mechanism of action**: they block direct tissue damage and down-regulate inflammation by acting upstream of multiple pro-inflammatory pathways[61](index=61&type=chunk) - Auxora is formulated as an **IV lipid nanoemulsion**, designed to facilitate rapid delivery to lipophilic organs such as the pancreas, lung, and kidney, which is critical for treating acute illnesses[63](index=63&type=chunk) [Manufacturing, Commercialization, and Competition](index=58&type=section&id=Item%201.%20Business-Manufacturing,%20Commercialization,%20and%20Competition) CalciMedica does not own manufacturing facilities and relies entirely on contract manufacturing organizations (CMOs) for the production of its product candidates - The company does not own or operate manufacturing facilities and relies on **CMOs** for all raw materials, drug substance, and drug product needs. It does not have long-term agreements with these third parties[185](index=185&type=chunk) - The company has not yet established a commercial organization or distribution capabilities and intends to build an internal infrastructure or collaborate with partners to support sales[181](index=181&type=chunk) - Competition comes from large pharmaceutical companies and other biotechs, including some developing **CRAC channel inhibitors** for various indications. For its lead indication, acute pancreatitis, most competitors focus on symptoms rather than being disease-modifying[186](index=186&type=chunk)[187](index=187&type=chunk)[188](index=188&type=chunk) [Intellectual Property](index=62&type=section&id=Item%201.%20Business-Intellectual%20Property) As of December 31, 2024, CalciMedica's intellectual property portfolio includes issued and pending patents in the U.S. and other countries covering compositions of matter, methods of use, formulations, and synthetic processes for Auxora and other product candidates - The company owns **four issued U.S. patents** and over **60 issued patents worldwide** for compositions covering Auxora, with expirations ranging from **2031 to 2036**[194](index=194&type=chunk) - For methods of using Auxora to treat acute pancreatitis (AP), the company owns **two issued U.S. patents** and over **30 issued patents worldwide**, with expected expirations between **2031-2046**[195](index=195&type=chunk) [Government Regulation](index=62&type=section&id=Item%201.%20Business-Government%20Regulation) CalciMedica is subject to extensive regulation by the FDA in the U.S. and similar authorities abroad - The company's products are subject to extensive regulation by the **FDA** and other government authorities, covering research, development, manufacturing, and marketing[200](index=200&type=chunk) - The FDA drug approval process generally involves preclinical studies, an Investigational New Drug (IND) application, and **three phases of human clinical trials** to establish safety and efficacy[204](index=204&type=chunk)[211](index=211&type=chunk) - The company has received **Fast Track designation** from the FDA and **orphan drug designation** in the EU from the EMA for Auxora for the treatment of acute pancreatitis[43](index=43&type=chunk)[223](index=223&type=chunk)[221](index=221&type=chunk) [Risk Factors](index=89&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks, including a history of significant net losses and the need for additional capital to fund operations and clinical trials - The company has a history of net losses, with an accumulated deficit of **$159.8 million** as of December 31, 2024, and anticipates incurring significant future losses[290](index=290&type=chunk) - Substantial additional funding is required to complete development and commercialization. Current resources are expected to fund operations into **mid-2026**, but are insufficient to get any product candidate through regulatory approval[292](index=292&type=chunk)[293](index=293&type=chunk) - The company's business is highly dependent on the success of its lead product candidate, **Auxora**, which may fail in development or not receive regulatory approval[311](index=311&type=chunk) - The company relies on **third parties** for manufacturing, preclinical studies, and clinical trials. Failure by these parties to perform adequately could delay development programs[375](index=375&type=chunk)[384](index=384&type=chunk) - The company faces risks of intellectual property challenges, including being unable to obtain and maintain sufficient patent protection, which could allow competitors to develop similar products[459](index=459&type=chunk) [Cybersecurity](index=142&type=section&id=Item%201C.%20Cybersecurity) CalciMedica has established a cybersecurity risk management program overseen by the Audit Committee of the Board of Directors - The **Audit Committee** of the Board of Directors is responsible for overseeing the company's cybersecurity risk management processes[552](index=552&type=chunk)[556](index=556&type=chunk) - The company utilizes a **third-party information technology consultant** to assist management in identifying, assessing, and managing cybersecurity threats[548](index=548&type=chunk)[549](index=549&type=chunk) - A **Cybersecurity Incident Response Policy** is in place to escalate and manage incidents, involving a team of senior management and the IT consultant[555](index=555&type=chunk) [Properties](index=143&type=section&id=Item%202.%20Properties) The company's corporate headquarters are located in La Jolla, California, where it leases approximately 2,850 square feet of office and laboratory space - CalciMedica leases approximately **2,850 square feet** of office and laboratory space for its headquarters in La Jolla, California[557](index=557&type=chunk) - The current lease for its facilities expires on **December 31, 2025**[557](index=557&type=chunk) [Legal Proceedings](index=144&type=section&id=Item%203.%20Legal%20Proceedings) As of the report date, CalciMedica believes there is no pending litigation that could, individually or in the aggregate, have a material adverse effect on its financial condition or results of operations - The company currently believes there is **no pending litigation** that could have a material adverse effect on its financial condition or results of operations[559](index=559&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=145&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) CalciMedica's common stock is traded on The Nasdaq Capital Market under the ticker symbol "CALC", with approximately 70 holders of record as of March 21, 2025 - The company's common stock trades on **The Nasdaq Capital Market** under the symbol '**CALC**'[562](index=562&type=chunk) - As of **March 21, 2025**, there were approximately **70 holders of record** of the common stock[562](index=562&type=chunk) - The company has never paid cash dividends and does not intend to in the foreseeable future[563](index=563&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=146&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For the year ended December 31, 2024, CalciMedica reported a net loss of $13.7 million, a significant reduction from the $34.4 million net loss in 2023 [Results of Operations](index=150&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations-Results%20of%20Operations) For the year ended December 31, 2024, CalciMedica's net loss decreased to $13.7 million from $34.4 million in 2023, primarily due to reduced general and administrative expenses Comparison of Results of Operations (in thousands) | | Year Ended Dec 31, 2024 | Year Ended Dec 31, 2023 | Change | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $14,478 | $15,859 | $(1,381) | (9%) | | General and administrative | $9,726 | $22,216 | $(12,490) | (56%) | | **Total operating expenses** | **$24,204** | **$38,075** | **$(13,871)** | **(36%)** | | **Loss from operations** | **$(24,204)** | **$(38,075)** | **$13,871** | **(36%)** | | Other income | $10,504 | $3,718 | $6,786 | 183% | | **Net loss** | **$(13,700)** | **$(34,357)** | **$20,657** | **(60%)** | - The **$12.5 million decrease** in G&A expenses was primarily due to a **$13.0 million reduction in personnel costs**. The 2023 figure included one-time charges for acceleration of stock option vesting (**$8.6 million**) and severance (**$4.1 million**) related to the merger[598](index=598&type=chunk) - The **$1.4 million decrease** in R&D expenses was mainly due to a **$3.3 million decrease in personnel expense**, which in 2023 included one-time merger-related charges for stock option vesting (**$1.9 million**) and severance (**$1.6 million**). This was partially offset by a **$1.3 million increase in manufacturing activities** in 2024[596](index=596&type=chunk)[597](index=597&type=chunk) [Liquidity and Capital Resources](index=151&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations-Liquidity%20and%20Capital%20Resources) As of December 31, 2024, the company had $18.7 million in cash, cash equivalents, and short-term investments, expected to fund operations into mid-2026 with a new loan - As of **December 31, 2024**, the company had cash, cash equivalents, and short-term investments of **$18.7 million**[600](index=600&type=chunk) - The company believes its existing cash plus a **February 2025 loan** will fund operations through certain clinical milestones into the **middle of 2026**[601](index=601&type=chunk) - In **February 2025**, the company entered into a loan agreement for up to **$32.5 million**, with an initial tranche of **$10.0 million** funded at closing[580](index=580&type=chunk)[611](index=611&type=chunk) Cash Flow Summary (in thousands) | | Year Ended Dec 31, 2024 | Year Ended Dec 31, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(21,146) | $(25,730) | | Net cash (used in) provided by investing activities | $(4,423) | $8,884 | | Net cash provided by financing activities | $27,974 | $20,900 | | **Net increase in cash and cash equivalents** | **$2,405** | **$4,054** | [Critical Accounting Estimates](index=155&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations-Critical%20Accounting%20Estimates) The company's critical accounting estimates involve significant management judgment, particularly for the accrual of research and development costs and the valuation of warrants - A key estimate is the accrual for **research and development costs**, especially for clinical trials, which is based on an evaluation of progress and services provided by vendors like CROs[625](index=625&type=chunk) - The valuation of **common stock warrants** is a critical estimate, calculated using the **Black-Scholes model**. Changes in assumptions like volatility or the probability of settlement scenarios can significantly impact the fair value and, consequently, the results of operations[628](index=628&type=chunk) [Financial Statements and Supplementary Data](index=157&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements of CalciMedica, Inc. for the fiscal years ended December 31, 2024, and 2023, including auditor reports and notes Consolidated Balance Sheet Data (in thousands) | | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $7,935 | $5,530 | | Short-term investments | $10,734 | $5,708 | | Total current assets | $19,665 | $11,605 | | **Total assets** | **$19,794** | **$12,185** | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $3,684 | $4,028 | | Warrant liability | $1,700 | $— | | **Total liabilities** | **$5,384** | **$4,028** | | **Total stockholders' equity** | **$14,410** | **$8,157** | Consolidated Statement of Operations Data (in thousands) | | Year Ended Dec 31, 2024 | Year Ended Dec 31, 2023 | | :--- | :--- | :--- | | Research and development | $14,478 | $15,859 | | General and administrative | $9,726 | $22,216 | | **Loss from operations** | **$(24,204)** | **$(38,075)** | | **Net loss** | **$(13,700)** | **$(34,357)** | | Net loss per share | $(1.22) | $(7.66) | [Controls and Procedures](index=157&type=section&id=Item%209A.%20Controls%20and%20Procedures) As of December 31, 2024, management concluded that the company's disclosure controls and procedures and internal control over financial reporting were effective - Management, including the CEO and CFO, concluded that the company's **disclosure controls and procedures were effective** as of December 31, 2024[636](index=636&type=chunk) - Based on an assessment using the **COSO 2013 framework**, management concluded that the company's **internal control over financial reporting was effective** as of December 31, 2024[638](index=638&type=chunk)[639](index=639&type=chunk) - **No material changes** in internal control over financial reporting occurred during the year ended December 31, 2024[640](index=640&type=chunk) [Other Information](index=158&type=section&id=Item%209B.%20Other%20Information) The company announced its 2025 Annual Meeting of Stockholders is intended for June 24, 2025, with new deadlines for stockholder proposals due to a date change - The **2025 Annual Meeting of Stockholders** is intended to be held on or about **June 24, 2025**[642](index=642&type=chunk) - The deadline for stockholder proposals under **Rule 14a-8** for the 2025 Annual Meeting is **March 18, 2025**[645](index=645&type=chunk) Part III Part III of this Annual Report on Form 10-K incorporates information by reference from the company's definitive Proxy Statement for its 2025 Annual Meeting of Stockholders, to be filed by April 30, 2025 [Directors, Executive Officers and Corporate Governance](index=159&type=section&id=Item%2010.%20Directors,%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance will be incorporated by reference from the company's 2025 proxy statement - Required information for this item is incorporated by reference from the company's **2025 Proxy Statement**[650](index=650&type=chunk) - The company has adopted a **Code of Conduct and Ethics**, available on its website, with disclosures for amendments or waivers for executive officers or directors[651](index=651&type=chunk) [Executive Compensation](index=159&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding executive and director compensation will be incorporated by reference from the company's 2025 proxy statement - Required information regarding executive compensation is incorporated by reference from the company's **2025 Proxy Statement**[652](index=652&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=159&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information detailing security ownership by certain beneficial owners and management, and equity compensation plans, will be incorporated by reference from the company's 2025 proxy statement - Required information regarding security ownership and equity compensation plans is incorporated by reference from the company's **2025 Proxy Statement**[653](index=653&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=159&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions,%20and%20Director%20Independence) Information concerning related-party transactions and director independence will be incorporated by reference from the company's 2025 proxy statement - Required information regarding related transactions and director independence is incorporated by reference from the company's **2025 Proxy Statement**[654](index=654&type=chunk) [Principal Accounting Fees and Services](index=159&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) Information detailing fees paid to and services provided by the principal independent registered public accounting firm will be incorporated by reference from the company's 2025 proxy statement - Required information regarding principal accountant fees and services is incorporated by reference from the company's **2025 Proxy Statement**[655](index=655&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=160&type=section&id=Item%2015.%20Exhibits,%20Financial%20Statement%20Schedules) This section lists the financial statements and exhibits filed with the Annual Report, including consolidated financial statements, auditor reports, and a detailed index of exhibits - This item includes the company's consolidated financial statements and the reports of its independent registered public accounting firms[661](index=661&type=chunk) - An index of all exhibits filed with the Form 10-K is provided, as required by **Item 601 of Regulation S-K**[662](index=662&type=chunk)[659](index=659&type=chunk)

[Executive Summary](index=1&type=section&id=Executive%20Summary) CalciMedica, a clinical-stage biopharmaceutical company, advances its Auxora™ Phase 2 KOURAGE trial and reports a 62.7% relative mortality reduction in the CARDEA trial for AKI [Company Introduction](index=1&type=section&id=Company%20Introduction) CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitor therapies for inflammatory and immunological diseases - CalciMedica is a clinical-stage biopharmaceutical company focused on developing CRAC channel inhibitor therapies for acute and chronic inflammatory and immunological diseases[2](index=2&type=chunk) [Key Highlights & CEO Statement](index=1&type=section&id=Key%20Highlights%20%26%20CEO%20Statement) Auxora™ Phase 2 KOURAGE trial for AKI and respiratory failure is on track for late 2025 data, with CARDEA trial analysis showing a 62.7% relative mortality reduction in AKI - Enrollment for the Phase 2 KOURAGE trial (Auxora™ for AKI and respiratory failure) is ongoing, with data expected in **late 2025**[1](index=1&type=chunk)[3](index=3&type=chunk) - Late-stage analysis of AKI patients in the Phase 2 CARDEA trial showed a **62.7% relative reduction** in mortality at 30 days, sustained through 60 days, for the Auxora treatment group[1](index=1&type=chunk)[3](index=3&type=chunk) - The company anticipates its existing cash position will support operations until **mid-2026**[1](index=1&type=chunk)[3](index=3&type=chunk) [Clinical & Corporate Updates](index=1&type=section&id=Clinical%20%26%20Corporate%20Updates) CalciMedica provided updates on Auxora™ clinical programs for AKI, AP, and AIPT, detailing trial enrollment, data timelines, and key late-stage analysis [Clinical Program Updates](index=1&type=section&id=Clinical%20Program%20Updates) CalciMedica provided updates on Auxora™ clinical programs for AKI, AP, and AIPT, detailing trial enrollment, data timelines, and key late-stage analysis [Acute Kidney Injury (AKI) Program Update](index=1&type=section&id=Acute%20Kidney%20Injury%20(AKI)%20Program%20Update) The Phase 2 KOURAGE trial for severe AKI with acute hypoxic respiratory failure is enrolling 150 patients, with data expected in late 2025, and CARDEA trial analysis showed significant mortality reduction - The Phase 2 KOURAGE trial for severe AKI with acute hypoxic respiratory failure is enrolling, targeting **150 patients**, with data expected in **late 2025**[4](index=4&type=chunk) - Late-stage analysis of AKI patients in the Phase 2 CARDEA trial showed a **62.7% relative reduction** and **29.3% absolute reduction** in mortality at 30 and 60 days for the Auxora treatment group[8](index=8&type=chunk) CARDEA Trial AKI Patient 30- and 60-Day Mortality | Group | Number of Deaths at 30 and 60 Days | Total Patients | Mortality Rate | | :---- | :--------------------------------- | :------------- | :------------- | | Placebo | 7 | 15 | 46.7% | | Auxora | 4 | 23 | 17.4% | [Acute Pancreatitis (AP) Program Update](index=2&type=section&id=Acute%20Pancreatitis%20(AP)%20Program%20Update) The company plans a Phase 2 end-of-study meeting with the FDA in mid-2025 and anticipates initiating a Phase 3 program for AP with SIRS by late 2025, subject to additional funding - The company plans a Phase 2 end-of-study meeting with the FDA in **mid-2025** and expects to initiate a Phase 3 program for AP with Systemic Inflammatory Response Syndrome (SIRS) by **late 2025**, contingent on additional funding[8](index=8&type=chunk) - Collaborator Prof. Robert Sutton presented a plenary session at the 2024 American Pancreatic Association (APA) annual meeting on Auxora's reduction of severe organ failure development in AP with SIRS patients[8](index=8&type=chunk) [Asparaginase-induced Pancreatic Toxicity (AIPT) Program Update](index=2&type=section&id=Asparaginase-induced%20Pancreatic%20Toxicity%20(AIPT)%20Program%20Update) Enrollment for the Phase 2 portion of the CRSPA study for AIPT is over 50% complete, with updates expected in H2 2025 - Enrollment for the Phase 2 portion of the CRSPA study for AIPT is over **50% complete**, with updates expected in the **second half of 2025**[6](index=6&type=chunk) [Corporate Updates](index=2&type=section&id=Corporate%20Updates) CalciMedica strengthened its leadership team with Stephen Bardin appointed CFO in November 2024 and Dr. Alan Glicklich joining the Board in January 2025 - In **November 2024**, Stephen Bardin was appointed Chief Financial Officer, bringing extensive experience in financing, corporate development, and strategic finance[9](index=9&type=chunk) - In **January 2025**, Dr. Alan Glicklich was appointed to the company's Board of Directors, with over **20 years of experience** in the biotechnology industry[9](index=9&type=chunk) [Other Business Highlights](index=3&type=section&id=Other%20Business%20Highlights) CalciMedica secured a credit agreement for up to $32.5 million with Avenue Venture Opportunities Fund II, L.P. on March 5, 2025, including an initial $10 million funding - On **March 5, 2025**, CalciMedica entered into a credit agreement for up to **$32.5 million** with a fund managed by Avenue Capital Group[10](index=10&type=chunk) - The **3.5-year** credit agreement includes an initial **$10 million** funding, with an additional **$22.5 million** available upon achieving specific milestones[10](index=10&type=chunk) [Financial Results](index=3&type=section&id=Financial%20Results) CalciMedica significantly reduced its net loss in FY2024 to $13.7 million from $34.4 million in 2023, driven by decreased R&D and G&A expenses and increased other income [2024 Financial Performance Summary](index=3&type=section&id=2024%20Financial%20Performance%20Summary) CalciMedica significantly reduced its net loss in FY2024 to $13.7 million from $34.4 million in 2023, driven by decreased R&D and G&A expenses and increased other income 2024 Key Financial Data (in thousands of US dollars) | Metric | 2024 | 2023 | Year-over-Year Change | | :--------------- | :----- | :----- | :-------------------- | | R&D Expenses | 14,478 | 15,859 | (1,381) | | G&A Expenses | 9,726 | 22,216 | (12,490) | | Other Income | 10,504 | 3,718 | 6,786 | | Net Loss | (13,700) | (34,357) | 20,657 | - As of **December 31, 2024**, cash, cash equivalents, and short-term investments totaled **$18.7 million**, which, combined with **$9.7 million** net proceeds from recent debt financing announced in March 2025, is expected to fund operations until **mid-2026**[11](index=11&type=chunk) - R&D expenses decreased by **$1.4 million**, primarily due to a **$3.3 million reduction** in one-time personnel costs from the Graybug Vision merger in 2023, partially offset by a **$1.3 million increase** in chemistry, manufacturing, and control activities for Auxora Phase 2 clinical trials[11](index=11&type=chunk) - G&A expenses decreased by **$12.5 million**, primarily due to a **$13.0 million reduction** in one-time merger-related personnel costs in 2023[11](index=11&type=chunk) - Other income increased by **$6.8 million**, primarily due to a **$9.5 million increase** in fair value adjustment of warrant liabilities from a private placement in 2024[11](index=11&type=chunk) [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2024, total assets increased to $19.794 million, driven by growth in cash and investments, while liabilities rose due to warrant liabilities, and stockholders' equity improved Consolidated Balance Sheet Key Data (in thousands of US dollars) | Metric | December 31, 2024 | December 31, 2023 | | :----------------------- | :---------------- | :---------------- | | Cash and cash equivalents | 7,935 | 5,530 | | Short-term investments | 10,734 | 5,708 | | Total current assets | 19,665 | 11,605 | | Total assets | 19,794 | 12,185 | | Total current liabilities | 3,684 | 4,028 | | Warrant liabilities | 1,700 | — | | Total liabilities | 5,384 | 4,028 | | Total stockholders' equity | 14,410 | 8,157 | [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) The company's net loss significantly narrowed to $13.7 million in FY2024 from $34.357 million in 2023, primarily due to reduced operating expenses and increased other income Consolidated Statements of Operations Key Data (in thousands of US dollars, except per share amounts) | Metric | Year Ended December 31, 2024 | Year Ended December 31, 2023 | | :--------------------------------- | :--------------------------- | :--------------------------- | | Research and development expenses | 14,478 | 15,859 | | General and administrative expenses | 9,726 | 22,216 | | Total operating expenses | 24,204 | 38,075 | | Operating loss | (24,204) | (38,075) | | Change in fair value of financial instruments | 9,490 | 3,168 | | Other income | 1,014 | 550 | | Total other income | 10,504 | 3,718 | | Net loss | (13,700) | (34,357) | | Net loss per share - basic and diluted | (1.22) | (7.66) | | Weighted-average shares used in computing net loss per share | 11,245,915 | 4,486,258 | [About CalciMedica](index=4&type=section&id=About%20CalciMedica) CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitor therapies to modulate immune responses and protect tissue cells, with Auxora™ showing positive results in trials [Company Profile and Product Pipeline](index=4&type=section&id=Company%20Profile%20and%20Product%20Pipeline) CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitor therapies to modulate immune responses and protect tissue cells, with Auxora™ showing positive results in trials - CalciMedica focuses on developing CRAC channel inhibitor therapies to modulate immune responses and protect tissue cells from damage, treating life-threatening inflammatory and immunological diseases[12](index=12&type=chunk) - The lead candidate Auxora™ has shown positive clinical results in Phase 2b/2 trials for acute pancreatitis (CARPO) and COVID pneumonia (CARDEA)[12](index=12&type=chunk) - Currently, Phase 2 KOURAGE trial (for AKI with AHRF, data expected late 2025) and Phase 1/2 CRSPA trial (for pediatric AIPT, updates expected 2025) are ongoing[12](index=12&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This report contains forward-looking statements regarding CalciMedica's cash flow, clinical trial timelines, Auxora's potential benefits, and future plans, subject to uncertainties and risks [Risks and Uncertainties](index=4&type=section&id=Risks%20and%20Uncertainties) This report contains forward-looking statements regarding CalciMedica's cash flow, clinical trial timelines, Auxora's potential benefits, and future plans, subject to uncertainties and risks - Forward-looking statements cover the company's cash flow expectations, clinical trial plans and timelines, potential benefits of Auxora, and future financing plans[13](index=13&type=chunk) - Actual results may differ materially from forward-looking statements due to uncertainties, risks, and changing circumstances[13](index=13&type=chunk) - Risks and uncertainties include global financial market volatility, the company's ability to execute plans, regulatory approvals for Auxora, clinical trial outcomes, potential safety complications, intellectual property protection, and the need for additional capital[13](index=13&type=chunk) [Contact Information](index=5&type=section&id=Contact%20Information) This section provides contact information for CalciMedica's investor relations, managed by Argot Partners [Investor Relations Contact](index=5&type=section&id=Investor%20Relations%20Contact) This section provides contact information for CalciMedica's investor relations, managed by Argot Partners - Investor Relations contacts: Sarah Sutton/Kevin Murphy (Argot Partners)[15](index=15&type=chunk) - Contact email: calcimedica@argotpartners.com, Phone: (212) 600-1902[15](index=15&type=chunk)

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number 001-39538 CalciMedica, Inc. (Exact name of Registrant as specified in its Charter) Delaware 45-2120079 (State or other jurisdict ...

[Overview and Highlights](index=1&type=section&id=Overview%20and%20Highlights) CalciMedica reported Q3 2024 results, highlighting positive CARPO Phase 2b trial data for Auxora and extended cash runway - Announced additional **positive data**, including a **win ratio analysis**, from the CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP), with plans to initiate a **Phase 3 program in 2025**[1](index=1&type=chunk)[2](index=2&type=chunk) - Enrollment is **ongoing** in the Phase 2 KOURAGE trial for acute kidney injury (AKI) and the Phase 2 CRSPA trial for asparaginase-induced pancreatic toxicity (AIPT), with data from both **expected in 2025**[1](index=1&type=chunk) - Completed a **public offering** in October, **strengthening the cash position** to fund operations into the **first half of 2026**[1](index=1&type=chunk)[7](index=7&type=chunk) [Clinical Updates and Pipeline Progress](index=1&type=section&id=Clinical%20Updates%20and%20Pipeline%20Progress) CalciMedica reported positive CARPO Phase 2b data for Auxora, with ongoing enrollment for KOURAGE and CRSPA trials [CARPO Phase 2b Trial (Acute Pancreatitis - AP)](index=1&type=section&id=CARPO%20Phase%202b%20Trial%20%28Acute%20Pancreatitis%20-%20AP%29) The CARPO trial for Auxora in AP showed statistically significant results, including a 100% relative risk reduction in severe respiratory failure - Auxora demonstrated a statistically significant **100% relative risk reduction** (p = 0.0027) in new-onset severe respiratory failure and a **64.2% reduction** (p = 0.0476) in new-onset persistent respiratory failure[7](index=7&type=chunk) - Analysis found a **statistically significant stratified win ratio of 1.640** (p = 0.0372) for high-dose Auxora patients compared to placebo patients[7](index=7&type=chunk) - The company is planning an **end-of-Phase 2 meeting with the FDA** and expects to be in a position to **initiate a Phase 3 program in 2025**[4](index=4&type=chunk) [KOURAGE Phase 2 Trial (Acute Kidney Injury - AKI)](index=2&type=section&id=KOURAGE%20Phase%202%20Trial%20%28Acute%20Kidney%20Injury%20-%20AKI%29) Enrollment continues for the KOURAGE Phase 2 trial of Auxora in severe AKI patients, with topline data expected in 2025 - The KOURAGE trial is evaluating Auxora in patients with **severe AKI (stage 2 and stage 3)** with associated acute hypoxemic respiratory failure (AHRF)[7](index=7&type=chunk) - The company expects to enroll **150 patients**, with **topline data expected in 2025**[7](index=7&type=chunk) [CRSPA Phase 2 Trial (AIPT)](index=2&type=section&id=CRSPA%20Phase%202%20Trial%20%28AIPT%29) Enrollment is ongoing for the CRSPA Phase 2 trial in AIPT, targeting 24 patients with data expected in 2025 - Enrollment is **ongoing** in the Phase 2 portion of the CRSPA study in asparaginase-induced pancreatic toxicity (AIPT)[7](index=7&type=chunk) - The trial is expected to enroll **approximately 24 patients**, and **data are expected in 2025**[7](index=7&type=chunk) [Financial Results and Corporate Updates](index=2&type=section&id=Financial%20Results%20and%20Corporate%20Updates) CalciMedica reported a Q3 2024 net loss of $5.6 million, with a public offering extending cash runway into H1 2026 [Financial Performance (Q3 2024)](index=2&type=section&id=Financial%20Performance%20%28Q3%202024%29) CalciMedica reported a Q3 2024 net loss of $5.6 million and a nine-month net loss of $9.4 million Financial Performance (Q3 2024) | Metric | Three Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2024 | | :--- | :--- | :--- | | **Loss from Operations** | $(5.7) million | $(18.0) million | | **Net Loss** | $(5.6) million | $(9.4) million | | **Net Loss Per Share** | $(0.50) | $(0.88) | [Financial Position and Liquidity](index=2&type=section&id=Financial%20Position%20and%20Liquidity) As of Sep 30, 2024, CalciMedica held $14.6 million in cash, with a public offering boosting pro-forma cash to $23.7 million - As of September 30, 2024, the company had approximately **$14.6 million** in cash, cash equivalents, and short-term investments[7](index=7&type=chunk) - A public offering completed on November 1, 2024, raised gross proceeds of **$10.2 million**[7](index=7&type=chunk) - The pro-forma cash balance of approximately **$23.7 million** is expected to fund current operations into the **first half of 2026**[7](index=7&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents CalciMedica's unaudited condensed consolidated financial statements as of and for Q3 and nine months ended Sep 30, 2024 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of Sep 30, 2024, CalciMedica reported total assets of $16.2 million, liabilities of $7.2 million, and equity of $9.0 million Condensed Consolidated Balance Sheets (in thousands) | Account (in thousands) | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $9,151 | $5,530 | | **Total current assets** | $15,686 | $11,605 | | **Total assets** | $16,212 | $12,185 | | **Total liabilities** | $7,182 | $4,028 | | **Total stockholders' equity** | $9,030 | $8,157 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q3 2024, net loss was $5.6 million; for nine months, net loss was $9.4 million, a significant decrease from 2023 Condensed Consolidated Statements of Operations (Three Months Ended) | Account (in thousands) | Three Months Ended Sep 30, 2024 | Three Months Ended Sep 30, 2023 | | :--- | :--- | :--- | | **Research and development** | $3,546 | $2,772 | | **General and administrative** | $2,190 | $2,061 | | **Loss from operations** | $(5,736) | $(4,833) | | **Net loss** | $(5,618) | $(4,619) | Condensed Consolidated Statements of Operations (Nine Months Ended) | Account (in thousands) | Nine Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2023 | | :--- | :--- | :--- | | **Loss from operations** | $(18,032) | $(33,756) | | **Change in fair value of financial instruments** | $7,790 | $3,168 | | **Net loss** | $(9,442) | $(30,211) | [About CalciMedica and Forward-Looking Statements](index=2&type=section&id=About%20CalciMedica%20and%20Forward-Looking%20Statements) This section provides CalciMedica's corporate overview as a clinical-stage biopharmaceutical company and outlines forward-looking statements [Company Profile](index=2&type=section&id=Company%20Profile) CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, with Auxora™ showing positive clinical results - CalciMedica is a **clinical-stage biopharmaceutical company** focused on developing **novel CRAC channel inhibition therapies** for inflammatory and immunologic diseases[8](index=8&type=chunk) - The company's lead product candidate, **Auxora™**, has demonstrated **positive and consistent clinical results** in multiple completed efficacy clinical trials, including for acute pancreatitis (CARPO) and COVID pneumonia (CARDEA)[8](index=8&type=chunk) [Forward-Looking Statements](index=3&type=section&id=Forward-Looking%20Statements) This section details forward-looking statements regarding cash runway, clinical trials, and regulatory plans, subject to inherent risks and uncertainties - Forward-looking statements cover **expected cash runway**, **clinical trial timing and design**, **plans for FDA meetings**, and the **potential benefits of Auxora**[9](index=9&type=chunk) - Actual outcomes may differ due to **risks** such as **global financial market fluctuations**, ability to obtain **regulatory approval**, and potential **safety complications** from Auxora[9](index=9&type=chunk)

PART I—FINANCIAL INFORMATION [Financial Statements (Unaudited)](index=8&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The unaudited financial statements as of June 30, 2024, show a reduced net loss and increased assets, with current cash sufficient for at least one year of operations [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands USD) | Account | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $5,056 | $5,530 | | Short-term investments | $14,081 | $5,708 | | Total current assets | $20,442 | $11,605 | | **Total assets** | **$21,052** | **$12,185** | | **Liabilities & Equity** | | | | Total current liabilities | $3,914 | $4,028 | | Warrant liability | $3,300 | $0 | | **Total liabilities** | **$7,214** | **$4,028** | | **Total stockholders' equity** | **$13,838** | **$8,157** | [Condensed Consolidated Statements of Operations](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Condensed Consolidated Statements of Operations (in thousands USD) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $4,157 | $3,814 | $7,101 | $10,305 | | General and administrative | $2,372 | $2,769 | $5,195 | $18,618 | | Loss from operations | $(6,529) | $(6,583) | $(12,296) | $(28,923) | | **Net loss** | **$(3,954)** | **$(6,304)** | **$(3,824)** | **$(25,592)** | | Net loss per share | $(0.36) | $(1.11) | $(0.37) | $(7.86) | [Condensed Consolidated Statements of Cash Flows](index=13&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Condensed Consolidated Statements of Cash Flows Highlights (in thousands USD) | Activity | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(11,507) | $(17,547) | | Net cash (used in) provided by investing activities | $(8,003) | $14,502 | | Net cash provided by financing activities | $19,036 | $20,653 | | **Net (decrease) increase in cash and cash equivalents** | **$(474)** | **$17,608** | - Financing activities in the first six months of 2024 were primarily driven by **$19.0 million** in net proceeds from the issuance of common stock. In the same period of 2023, financing activities included **$14.9 million** in cash acquired from the Graybug merger and **$10.3 million** from a private placement[41](index=41&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=15&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) - The company is a clinical-stage biopharmaceutical firm focused on therapeutics for inflammatory processes, having completed a reverse merger with Graybug Vision, Inc. on March 20, 2023, with Private CalciMedica as the accounting acquirer[44](index=44&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk) - As of June 30, 2024, the company had an accumulated deficit of **$149.9 million**, with management believing its **$19.1 million** in cash, cash equivalents, and short-term investments are sufficient to fund operations for at least one year from the financial statement issuance date[47](index=47&type=chunk)[49](index=49&type=chunk)[51](index=51&type=chunk) - In January and February 2024, the company completed a private placement, raising gross proceeds of **$20.4 million** and net proceeds of approximately **$19.0 million**[121](index=121&type=chunk)[123](index=123&type=chunk) - The company has an At-the-Market (ATM) facility to sell up to **$17.3 million** of common stock, with approximately **$17.0 million** remaining available as of June 30, 2024[125](index=125&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=39&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical development of Auxora for inflammatory diseases and its financial performance, highlighting reduced net losses and extended cash runway from recent financing [Overview](index=39&type=section&id=Overview) - CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapeutics targeting calcium release-activated calcium (CRAC) channels for inflammatory and immunologic diseases[156](index=156&type=chunk)[157](index=157&type=chunk) - The lead product candidate, Auxora, is an intravenous CRAC channel inhibitor currently being evaluated in multiple Phase 2 trials for acute pancreatitis (AP), asparaginase-induced pancreatotoxicity (AIPT), and acute kidney injury (AKI)[158](index=158&type=chunk)[159](index=159&type=chunk)[160](index=160&type=chunk)[161](index=161&type=chunk) - The company plans to initiate a pivotal trial for Auxora in AP in 2025 and anticipates data from the AIPT and AKI trials in the same year[159](index=159&type=chunk)[160](index=160&type=chunk)[161](index=161&type=chunk) - As of June 30, 2024, the company reported an accumulated deficit of **$149.9 million** and held **$19.1 million** in cash, cash equivalents, and short-term investments[167](index=167&type=chunk) [Results of Operations](index=46&type=section&id=Results%20of%20Operations) Comparison of Operating Results (in thousands USD) | Period | Research & Development | General & Administrative | Total Operating Expenses | Net Loss | | :--- | :--- | :--- | :--- | :--- | | **Q2 2024** | $4,157 | $2,372 | $6,529 | $(3,954) | | **Q2 2023** | $3,814 | $2,769 | $6,583 | $(6,304) | | **H1 2024** | $7,101 | $5,195 | $12,296 | $(3,824) | | **H1 2023** | $10,305 | $18,618 | $28,923 | $(25,592) | - The decrease in G&A expenses for the six months ended June 30, 2024, compared to 2023, was primarily due to one-time merger-related charges in 2023, including **$8.6 million** for accelerated stock option vesting and **$4.1 million** in severance[189](index=189&type=chunk) - The increase in Other Income for H1 2024 was mainly due to a **$7.9 million** gain from the fair value adjustment of the warrant liability resulting from the 2024 Private Placement[190](index=190&type=chunk) [Liquidity and Capital Resources](index=48&type=section&id=Liquidity%20and%20Capital%20Resources) - As of June 30, 2024, the company held **$19.1 million** in cash, cash equivalents, and short-term investments[191](index=191&type=chunk) - In January/February 2024, the company raised approximately **$19.0 million** in net proceeds from a private placement[192](index=192&type=chunk)[201](index=201&type=chunk) - Management believes current cash resources are sufficient to fund operations into the second half of 2025, covering the advancement of Auxora through key clinical milestones in AP, AIPT, and AKI[193](index=193&type=chunk) - Net cash used in operating activities was **$11.5 million** for the first six months of 2024, a decrease from **$17.5 million** for the same period in 2023[203](index=203&type=chunk)[205](index=205&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=57&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, CalciMedica is not required to provide quantitative and qualitative disclosures regarding market risk - As a smaller reporting company, CalciMedica is not required to provide quantitative and qualitative disclosures about market risk[223](index=223&type=chunk) [Controls and Procedures](index=57&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2024, with no material changes to internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2024[225](index=225&type=chunk) - There were no changes in internal control over financial reporting during the quarter that materially affected or are reasonably likely to materially affect the company's internal controls[226](index=226&type=chunk) PART II—OTHER INFORMATION [Legal Proceedings](index=58&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no current litigation expected to have a material adverse effect on its financial condition or results of operations - The company states it currently has no pending litigation expected to have a material adverse effect on its financial position or operational results[230](index=230&type=chunk) [Risk Factors](index=59&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks including a history of net losses, the need for substantial additional funding, high dependence on Auxora's success, and challenges in clinical development, manufacturing, and intellectual property protection - The company is a clinical-stage entity with a limited operating history, a history of net losses, and an accumulated deficit of **$149.9 million** as of June 30, 2024, having never generated product revenue[234](index=234&type=chunk)[235](index=235&type=chunk) - Substantial additional funding is required to complete development and commercialization, as current cash is expected to fund operations only into the second half of 2025 and is insufficient for regulatory approval of any product candidate[237](index=237&type=chunk)[240](index=240&type=chunk) - The business is highly dependent on the success of its lead product candidate, Auxora, and failure to successfully develop and obtain regulatory approval would significantly harm the company[257](index=257&type=chunk)[259](index=259&type=chunk) - The company relies on third parties for manufacturing and conducting clinical trials, and any inadequate performance could delay development programs and increase costs[324](index=324&type=chunk)[331](index=331&type=chunk) - The company's ability to commercialize products may be adversely affected if it cannot obtain and maintain sufficient intellectual property protection for its candidates and technologies[406](index=406&type=chunk)[407](index=407&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=142&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities during the reporting period[495](index=495&type=chunk)

PART I—FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=9&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Presents CalciMedica's unaudited condensed consolidated financial statements and detailed notes for Q1 2024 and 2023 [Condensed Consolidated Balance Sheets](index=9&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Summarizes CalciMedica's assets, liabilities, and equity at March 31, 2024, and December 31, 2023 Condensed Consolidated Balance Sheets (in thousands) | Metric | March 31, 2024 | December 31, 2023 | | :-------------------------------- | :------------- | :---------------- | | Cash and cash equivalents | $6,755 | $5,530 | | Short-term investments | $18,955 | $5,708 | | Total current assets | $26,604 | $11,605 | | Total assets | $27,134 | $12,185 | | Total current liabilities | $4,287 | $4,028 | | Warrant liability | $5,600 | — | | Total liabilities | $9,887 | $4,028 | | Total stockholders' equity | $17,247 | $8,157 | - Total assets increased significantly from **$12.185 million** at December 31, 2023, to **$27.134 million** at March 31, 2024, primarily driven by an increase in short-term investments and cash and cash equivalents[26](index=26&type=chunk) - A new warrant liability of **$5.6 million** was recognized as of March 31, 2024, contributing to the increase in total liabilities[26](index=26&type=chunk) [Condensed Consolidated Statements of Operations](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Reports CalciMedica's revenues, expenses, and net income (loss) for the three months ended March 31, 2024, and 2023 Condensed Consolidated Statements of Operations (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Research and development | $2,944 | $6,491 | | General and administrative | $2,823 | $15,849 | | Total operating expenses | $5,767 | $22,340 | | Loss from operations | $(5,767) | $(22,340) | | Change in fair value of financial instruments | $5,590 | $3,168 | | Net income (loss) | $130 | $(19,288) | | Basic EPS | $0.01 | $(23.43) | | Diluted EPS | $0.01 | $(23.43) | - The company reported a net income of **$0.130 million** for the three months ended March 31, 2024, a significant improvement from a net loss of **$19.288 million** in the same period of 2023[29](index=29&type=chunk) - Total operating expenses decreased by **74%** from **$22.340 million** in Q1 2023 to **$5.767 million** in Q1 2024, primarily due to lower general and administrative expenses[29](index=29&type=chunk)[183](index=183&type=chunk) - A substantial gain from the change in fair value of financial instruments (**$5.590 million** in Q1 2024 vs. **$3.168 million** in Q1 2023) significantly contributed to the net income[29](index=29&type=chunk) [Condensed Consolidated Statement of Comprehensive Income (Loss)](index=11&type=section&id=Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income%20%28Loss%29) Details CalciMedica's net income (loss) and other comprehensive income (loss) for Q1 2024 and 2023 Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net income (loss) | $130 | $(19,288) | | Unrealized loss on available-for-sale securities, net of tax | $(19) | — | | Comprehensive income (loss) | $111 | $(19,288) | - Comprehensive income for Q1 2024 was **$0.111 million**, compared to a comprehensive loss of **$19.288 million** in Q1 2023, reflecting the improved net income and a minor unrealized loss on available-for-sale securities[32](index=32&type=chunk) [Condensed Consolidated Statements of Stockholders' Equity (Deficit)](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity%20%28Deficit%29) Details changes in CalciMedica's stockholders' equity (deficit) for Q1 2024 and 2023 Changes in Stockholders' Equity (Deficit) (in thousands) | Metric | Balance Dec 31, 2023 | Stock-based Comp | Private Placement Shares | Warrants Issuance | Unrealized Loss | Net Income | Balance Mar 31, 2024 | | :-------------------------------- | :------------------- | :--------------- | :----------------------- | :---------------- | :-------------- | :--------- | :------------------- | | Common Stock Amount | $1 | — | $2 | — | — | — | $3 | | Additional Paid-In Capital | $154,218 | $414 | $7,903 | $660 | — | — | $163,195 | | Accumulated Deficit | $(146,064) | — | — | — | — | $130 | $(145,934) | | Accumulated Other Comprehensive Loss | $2 | — | — | — | $(19) | — | $(17) | | Total Stockholders' Equity | $8,157 | $414 | $7,905 | $660 | $(19) | $130 | $17,247 | - Total stockholders' equity increased from **$8.157 million** at December 31, 2023, to **$17.247 million** at March 31, 2024, primarily due to the issuance of common shares from a private placement (**$7.905 million**) and warrants (**$0.660 million**), along with net income[34](index=34&type=chunk) - The accumulated deficit decreased slightly from **$146.064 million** to **$145.934 million**, reflecting the net income for the quarter[34](index=34&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=14&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Summarizes CalciMedica's cash flows from operating, investing, and financing activities for Q1 2024 and 2023 Condensed Consolidated Statements of Cash Flows (in thousands) | Activity | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net cash used in operating activities | $(4,715) | $(5,355) | | Net cash provided by (used in) investing activities | $(13,103) | $4,750 | | Net cash provided by financing activities | $19,043 | $23,515 | | Net increase in cash and cash equivalents | $1,225 | $22,910 | | Cash and cash equivalents at end of period | $6,755 | $24,386 | - Net cash used in operating activities decreased from **$5.355 million** in Q1 2023 to **$4.715 million** in Q1 2024[41](index=41&type=chunk)[202](index=202&type=chunk)[203](index=203&type=chunk) - Investing activities shifted from providing **$4.750 million** in Q1 2023 to using **$13.103 million** in Q1 2024, primarily due to increased purchases of investments[41](index=41&type=chunk)[204](index=204&type=chunk) - Financing activities provided **$19.043 million** in Q1 2024, mainly from the 2024 Private Placement, compared to **$23.515 million** in Q1 2023, which included cash acquired from the Merger[41](index=41&type=chunk)[205](index=205&type=chunk)[206](index=206&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=16&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Provides detailed explanations and disclosures supporting the condensed consolidated financial statements [1. Nature of Business](index=16&type=section&id=1.%20Nature%20of%20Business) Describes CalciMedica's operations as a clinical-stage biopharmaceutical company and its financial position - CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory processes and cellular damage, specifically targeting CRAC channels[43](index=43&type=chunk) - The company completed a reverse merger with Graybug Vision, Inc. on March 20, 2023, with Private CalciMedica treated as the accounting acquirer, resulting in former Private CalciMedica equity holders owning **72%** of the combined company[44](index=44&type=chunk)[45](index=45&type=chunk) - As of March 31, 2024, the company had an accumulated deficit of **$145.9 million** but reported a net income of **$0.1 million** for the three months ended March 31, 2024, primarily due to a fair value adjustment to warrant liability and interest income[46](index=46&type=chunk) - Management believes current cash, cash equivalents, and short-term investments of **$25.7 million** (as of March 31, 2024) are sufficient to fund operations for at least one year, but additional funding will be required for product development and commercialization[48](index=48&type=chunk)[49](index=49&type=chunk)[50](index=50&type=chunk) [2. Summary of Significant Accounting Policies](index=16&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) Outlines the key accounting principles and methods used in preparing the financial statements - The condensed consolidated financial statements are prepared in conformity with U.S. GAAP and include the accounts of Graybug Vision, Inc. and CalciMedica Subsidiary, Inc. for the three months ended March 31, 2024 and 2023[51](index=51&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - The company manages its operations as a single segment, focusing on developing CRAC channel inhibitors, with no revenue generated since inception and all tangible assets held in the United States[61](index=61&type=chunk) - Research and development costs, including salaries, consultant fees, and laboratory supplies, are expensed as incurred[67](index=67&type=chunk) - Warrant liabilities are recognized at fair value on the balance sheet, with changes in fair value recorded in other income (expense) in the statements of operations[72](index=72&type=chunk)[73](index=73&type=chunk) - The company adopted ASU 2020-06 as of January 1, 2024, which simplified accounting for certain financial instruments with liability and equity characteristics, without material impact on its financial statements[90](index=90&type=chunk) [3. Merger and Related Transactions](index=24&type=section&id=3.%20Merger%20and%20Related%20Transactions) Details the reverse merger with Graybug Vision, Inc. and its financial implications - The Merger on March 20, 2023, was accounted for as a reverse recapitalization, with Private CalciMedica as the accounting acquirer, resulting in its stockholders owning approximately **72%** of the combined company[91](index=91&type=chunk)[93](index=93&type=chunk) - As part of the reverse recapitalization, Private CalciMedica received **$29.4 million** in cash, cash equivalents, and short-term investments, net of transaction costs[94](index=94&type=chunk) - The company incurred one-time charges of **$10.5 million** for accelerated Graybug stock awards and **$5.7 million** in severance charges for the three months ended March 31, 2023, due to the Merger[95](index=95&type=chunk) - A **14:1** reverse stock split of Graybug's common stock was effected on March 17, 2023, in connection with the Merger[96](index=96&type=chunk) [4. Fair Value Measurements](index=26&type=section&id=4.%20Fair%20Value%20Measurements) Details valuation methods and categorization of financial assets and liabilities measured at fair value - The company's financial assets and liabilities measured at fair value include short-term investments and warrants for common stock, revalued at each measurement period[97](index=97&type=chunk) - Fair value measurements are categorized into Level 1 (quoted prices in active markets), Level 2 (observable inputs other than Level 1), and Level 3 (unobservable inputs)[102](index=102&type=chunk)[104](index=104&type=chunk) Financial Assets Measured at Fair Value (March 31, 2024, in thousands) | Asset Type | Level 1 | Level 2 | Level 3 | Total | | :----------------------- | :------ | :------ | :------ | :------ | | Money market funds | $6,133 | — | — | $6,133 | | Commercial paper (Cash Eq.) | — | $500 | — | $500 | | Corporate debt securities | — | $1,210 | — | $1,210 | | Commercial paper (ST Inv.) | — | $17,745 | — | $17,745 | | Total assets | $6,133 | $19,455 | — | $25,588 | Financial Liabilities Measured at Fair Value (March 31, 2024, in thousands) | Liability Type | Level 1 | Level 2 | Level 3 | Total | | :--------------- | :------ | :------ | :------ | :------ | | Warrant Liability | — | — | $5,600 | $5,600 | - The warrant liability of **$5.6 million** as of March 31, 2024, is classified as Level 3, reflecting the use of unobservable inputs in its valuation[107](index=107&type=chunk)[108](index=108&type=chunk) [5. Convertible Promissory Notes and Convertible Promissory Note Warrants](index=28&type=section&id=5.%20Convertible%20Promissory%20Notes%20and%20Convertible%20Promissory%20Note%20Warrants) Details the terms and conversion of convertible promissory notes and warrants before the Merger - In April 2022, Private CalciMedica approved a convertible promissory note financing of up to **$5.0 million**, later amended to **$8.5 million**, with notes convertible into common stock and Convertible Promissory Note Warrants[109](index=109&type=chunk)[110](index=110&type=chunk) - Immediately prior to the Merger, all outstanding convertible promissory notes and accrued interest automatically converted into **590,031** shares of Graybug common stock[111](index=111&type=chunk) - Convertible Promissory Note Warrants, initially classified as a liability, were automatically net exercised into **152,875** shares of Graybug common stock prior to the Merger[112](index=112&type=chunk)[113](index=113&type=chunk) [6. Accrued Expenses](index=30&type=section&id=6.%20Accrued%20Expenses) Provides a breakdown of accrued liabilities, including payroll, professional fees, and other expenses Accrued Expenses (in thousands) | Category | March 31, 2024 | March 31, 2023 | | :----------------------------- | :------------- | :------------- | | Accrued payroll and other employee benefits | $1,126 | $935 | | Accrued severance | $22 | $89 | | Accrued professional fees | $507 | $345 | | Accrued franchise tax | $49 | $77 | | Accrued other | $48 | $22 | | Total accrued expenses | $1,752 | $1,468 | - Total accrued expenses increased from **$1.468 million** in Q1 2023 to **$1.752 million** in Q1 2024, primarily driven by increases in accrued payroll and professional fees[114](index=114&type=chunk) [7. Convertible Preferred Stock, Common Stock and Stockholders' Deficit](index=30&type=section&id=7.%20Convertible%20Preferred%20Stock%2C%20Common%20Stock%20and%20Stockholders%27%20Deficit) Details the company's capital structure, stock issuances, and warrant classifications - The company's authorized capital stock includes **500,000,000** shares of common stock and **10,000,000** shares of preferred stock, both with a par value of **$0.0001** per share[115](index=115&type=chunk) - Prior to the Merger, **84,820,880** shares of Private CalciMedica preferred stock were converted into common stock, which were then exchanged for **2,442,852** shares of Graybug's common stock[116](index=116&type=chunk) - In January/February 2024, the company completed a private placement, issuing **4,985,610** shares of common stock, **306,506** Pre-Funded Warrants, and Tranche A and B Common Warrants, generating net proceeds of approximately **$19.0 million**[119](index=119&type=chunk)[121](index=121&type=chunk) - The company has a shelf registration statement allowing for the offering of up to **$100.0 million** in securities, with **$99.7 million** remaining available as of March 31, 2024, and an at-the-market (ATM) facility for up to **$17.3 million** of common stock, with **$17.1 million** remaining[122](index=122&type=chunk)[123](index=123&type=chunk) - Tranche A and B Common Warrants issued in the 2024 Private Placement are classified as liabilities, with fair values of **$1.4 million** and **$4.2 million**, respectively, as of March 31, 2024, reflecting changes in fair value recorded in operations[129](index=129&type=chunk)[130](index=130&type=chunk) [8. Stock-based Compensation](index=34&type=section&id=8.%20Stock-based%20Compensation) Explains the company's equity incentive plans and the accounting for stock-based compensation expenses - The company operates under the 2006 Equity Incentive Plan (assumed from Private CalciMedica) and the 2023 Equity Incentive Plan, which became effective at the Merger closing, with **91,516** shares available for grant under the 2023 Plan as of March 31, 2024[133](index=133&type=chunk)[134](index=134&type=chunk) Stock Option Transactions (2023 Plan) | Metric | Total Options | Weighted Average Exercise Price | | :-------------------------- | :------------ | :------------------------------ | | Outstanding at Dec 31, 2023 | 1,739,270 | $15.71 | | Granted | 595,250 | $4.16 | | Cancelled | (223,308) | $76.63 | | Outstanding at Mar 31, 2024 | 2,111,212 | $6.01 | | Vested and exercisable at Mar 31, 2024 | 883,869 | $7.18 | Stock-based Compensation Expense (in thousands) | Category | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :----------------------------- | :-------------------------------- | :-------------------------------- | | Research and development | $171 | $2,080 | | General and administrative | $243 | $9,046 | | Total stock-based compensation expense | $414 | $11,126 | - Total stock-based compensation expense decreased significantly from **$11.126 million** in Q1 2023 to **$0.414 million** in Q1 2024, primarily due to one-time charges related to the acceleration of Graybug stock options vesting in 2023[139](index=139&type=chunk) [9. Commitments and Contingencies](index=37&type=section&id=9.%20Commitments%20and%20Contingencies) Outlines contractual obligations, lease agreements, and potential legal contingencies - The company has ongoing contracts with contract development and manufacturing organizations (CDMOs) and vendors for preclinical research and manufacturing, with approximately **$1.1 million** and **$1.2 million** of associated costs still in effect for future services as of March 31, 2024[143](index=143&type=chunk) - The company leases office space in La Jolla, California, under a short-term operating lease, with monthly rent of approximately **$10,000**[145](index=145&type=chunk) - Rent expense for the three months ended March 31, 2024, was **$30,000**, a decrease from **$65,000** in the same period of 2023[146](index=146&type=chunk) [10. Employee Benefits](index=38&type=section&id=10.%20Employee%20Benefits) Describes the company's defined contribution 401(k) plan for employees - The company adopted a defined contribution 401(k) plan in January 2007 for substantially all employees[147](index=147&type=chunk) - No contributions were made by the company to the 401(k) plan for the three months ended March 31, 2024, and 2023[147](index=147&type=chunk) [11. Income Taxes](index=38&type=section&id=11.%20Income%20Taxes) Discusses the company's income tax position, including deferred tax assets and valuation allowances - The company did not record a provision or benefit for income taxes during the three months ended March 31, 2024, and 2023, due to continuing losses[148](index=148&type=chunk) - A full valuation allowance is maintained against all deferred tax assets due to the history of cumulative net losses[148](index=148&type=chunk) [12. Net Income (Loss) Per Share](index=38&type=section&id=12.%20Net%20Income%20%28Loss%29%20Per%20Share) Presents the calculation of basic and diluted net income (loss) per share for common stockholders Net Income (Loss) Per Share (in thousands, except per share amounts) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | | Net Income (loss) | $130 | $(19,288) | | Weighted-average common shares outstanding, basic | 9,754,517 | 823,069 | | Weighted-average common shares outstanding, diluted | 10,047,415 | 823,069 | | Basic EPS | $0.01 | $(23.43) | | Diluted EPS | $0.01 | $(23.43) | - Basic and diluted EPS for Q1 2024 were **$0.01**, a significant improvement from **$(23.43)** in Q1 2023[149](index=149&type=chunk) - Potentially dilutive shares, including stock options and warrants, were excluded from diluted EPS calculation in Q1 2023 due to their anti-dilutive effect during a net loss period[151](index=151&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=41&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's analysis of CalciMedica's financial condition, operations, and liquidity for Q1 2024 and 2023 [Overview](index=41&type=section&id=Overview) Provides a high-level summary of CalciMedica's business, product candidates, and key financial highlights for Q1 2024 - CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitors for serious inflammatory and immunologic illnesses[153](index=153&type=chunk)[154](index=154&type=chunk) - Auxora, the lead product candidate, is an intravenous CRAC channel inhibitor in Phase 2 clinical development for acute pancreatitis (AP), asparaginase pancreatic toxicity (AIPT), and acute kidney injury (AKI)[155](index=155&type=chunk)[156](index=156&type=chunk)[157](index=157&type=chunk)[158](index=158&type=chunk)[160](index=160&type=chunk) - Topline results for the CARPO Phase 2b trial in AP are anticipated in **Q2 2024**, with a Phase 3 trial planned for **2025**; patient enrollment for the KOURAGE Phase 2 trial in AKI is expected to begin in **Q2 2024**[156](index=156&type=chunk)[160](index=160&type=chunk) - The company reported a net income of **$0.1 million** for Q1 2024, primarily due to a **$5.6 million** gain from fair value adjustment to warrant liability and **$0.3 million** in interest income, offsetting **$5.8 million** in operating expenses[166](index=166&type=chunk) - As of March 31, 2024, the company had an accumulated deficit of **$145.9 million** and **$25.7 million** in cash, cash equivalents, and short-term investments[166](index=166&type=chunk) [Components of Operating Results](index=45&type=section&id=Components%20of%20Operating%20Results) Explains the nature and drivers of CalciMedica's R&D, G&A, and other income (expense) categories - Research and development (R&D) expenses include personnel costs, fees to consultants and contract organizations, manufacturing costs for preclinical and clinical materials, and laboratory expenses[171](index=171&type=chunk)[175](index=175&type=chunk) - R&D expenses are expected to increase substantially as product candidates advance through clinical trials and regulatory approvals[173](index=173&type=chunk)[179](index=179&type=chunk) - General and administrative (G&A) expenses primarily cover personnel costs, professional services (legal, audit, accounting), and facility-related fees, and are also expected to increase due to public company operations and growth[180](index=180&type=chunk) - Other income (expense) includes interest income and changes in the fair value of warrant liabilities and convertible promissory notes[181](index=181&type=chunk) [Results of Operations](index=48&type=section&id=Results%20of%20Operations) Compares CalciMedica's operating expenses and net income (loss) for Q1 2024 and 2023 Results of Operations (in thousands) | Metric | Q1 2024 | Q1 2023 | Change Amount | Change % | | :-------------------------- | :------ | :------ | :------------ | :------- | | Research and development | $2,944 | $6,491 | $(3,547) | (55%) | | General and administrative | $2,823 | $15,849 | $(13,026) | (82%) | | Total operating expenses | $5,767 | $22,340 | $(16,573) | (74%) | | Loss from operations | $(5,767) | $(22,340) | $16,573 | (74%) | | Other income (expense), net | $5,897 | $3,052 | $2,845 | 93% | | Net income (loss) | $130 | $(19,288) | $19,418 | (101%) | - Research and development expenses decreased by **$3.6 million** (**55%**) in Q1 2024 compared to Q1 2023, primarily due to one-time charges in 2023 related to stock option acceleration and severance from the Merger[184](index=184&type=chunk) - General and administrative expenses decreased by **$13.0 million** (**82%**) in Q1 2024, mainly due to a **$13.9 million** reduction in personnel costs from one-time Merger-related charges in 2023, partially offset by increased professional services[185](index=185&type=chunk) - Net other income increased by **$2.8 million** (**93%**) in Q1 2024, driven by a **$5.6 million** gain from fair value adjustments to warrant liability, partially offset by a **$3.2 million** gain from warrant liability and convertible notes in Q1 2023[186](index=186&type=chunk) [Liquidity and Capital Resources](index=50&type=section&id=Liquidity%20and%20Capital%20Resources) Discusses CalciMedica's cash position, funding requirements, and capital sources for future operations - As of March 31, 2024, CalciMedica had **$25.7 million** in cash, cash equivalents, and short-term investments[188](index=188&type=chunk) - The company believes its current resources, including **$19.0 million** net proceeds from the 2024 Private Placement, are sufficient to fund operations into the **second half of 2025**, covering clinical milestones for Auxora in AP, AIPT, and AKI[189](index=189&type=chunk) - Substantial additional funding will be required to complete development and commercialization of product candidates, as current funds are insufficient for regulatory approval or expanding into new indications[189](index=189&type=chunk)[190](index=190&type=chunk) - Future funding requirements are dependent on clinical trial progress, regulatory review, manufacturing arrangements, and potential collaborations[191](index=191&type=chunk)[192](index=192&type=chunk) - Cash used in operating activities was **$4.7 million** in Q1 2024, while financing activities provided **$19.0 million**, primarily from the 2024 Private Placement[201](index=201&type=chunk)[202](index=202&type=chunk)[205](index=205&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=55&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) Details critical accounting policies and significant management judgments and estimates in financial reporting - The preparation of financial statements requires management to make estimates and assumptions, particularly for research and development costs and the valuation of warrants[211](index=211&type=chunk) - Research and development costs, especially those from CROs and external vendors, are estimated based on services performed, progress to completion, and budget, with adjustments made as actual costs become known[212](index=212&type=chunk)[213](index=213&type=chunk)[214](index=214&type=chunk) - Common Warrants are valued using the Black-Scholes model, incorporating inputs like risk-free interest rate, volatility, exercise price, and stock price, with fair value changes impacting results of operations[215](index=215&type=chunk) - CalciMedica is an 'emerging growth company' and 'smaller reporting company,' allowing it to delay adopting new accounting standards and benefit from reduced disclosure requirements[216](index=216&type=chunk)[217](index=217&type=chunk) [Recently Adopted Accounting Pronouncements](index=57&type=section&id=Recently%20Adopted%20Accounting%20Pronouncements) Refers to Note 2 for details on new accounting standards adopted by the company - Refer to Note 2 of the condensed consolidated financial statements for information on recently adopted accounting pronouncements[218](index=218&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=58&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) CalciMedica, as a smaller reporting company, is exempt from providing market risk disclosures - CalciMedica is a smaller reporting company and is exempt from providing quantitative and qualitative disclosures about market risk[219](index=219&type=chunk) [Item 4. Controls and Procedures](index=58&type=section&id=Item%204.%20Controls%20and%20Procedures) Details the evaluation of CalciMedica's disclosure controls and internal control over financial reporting [Evaluation of Disclosure Controls and Procedures](index=58&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) Reports on management's assessment of disclosure controls and procedures effectiveness as of March 31, 2024 - Management, with the CEO and Interim CFO's participation, evaluated disclosure controls and procedures as of March 31, 2024[220](index=220&type=chunk) - Based on the evaluation, disclosure controls and procedures were concluded to be effective at a reasonable assurance level[221](index=221&type=chunk) [Changes in Internal Control over Financial Reporting](index=58&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) Confirms no material changes in internal control over financial reporting during Q1 2024 - There were no changes in internal control over financial reporting during Q1 2024 that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[222](index=222&type=chunk) PART II—OTHER INFORMATION [Item 1. Legal Proceedings](index=59&type=section&id=Item%201.%20Legal%20Proceedings) No pending litigation is believed to have a material adverse effect on the company's financial condition - The company may be involved in legal proceedings in the ordinary course of business, with uncertain outcomes that could negatively impact financial results[225](index=225&type=chunk) - Currently, there is no litigation pending that is believed to have a material adverse effect on the company's results of operations or financial condition[226](index=226&type=chunk) [Item 1A. Risk Factors](index=60&type=section&id=Item%201A.%20Risk%20Factors) Outlines significant risks related to CalciMedica's business, financial condition, and common stock investment [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements](index=60&type=section&id=Risks%20Related%20to%20Our%20Limited%20Operating%20History%2C%20Financial%20Position%20and%20Capital%20Requirements) Discusses risks from limited operating history, substantial funding needs, and potential dilution - CalciMedica is a clinical-stage biopharmaceutical company with a limited operating history, **no product revenue**, and a history of net losses, anticipating significant future losses[230](index=230&type=chunk)[231](index=231&type=chunk) - The company will require substantial additional funding beyond its current **$25.7 million** in cash, cash equivalents, and short-term investments to complete product development and commercialization, with current funds only sufficient into the **second half of 2025**[233](index=233&type=chunk)[236](index=236&type=chunk) - Raising additional capital may dilute stockholders, restrict operations through debt covenants, or require relinquishing rights to proprietary platforms or product candidates[241](index=241&type=chunk)[242](index=242&type=chunk) - Any acquisitions or strategic collaborations could increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities[244](index=244&type=chunk)[245](index=245&type=chunk) - Failure to maintain Nasdaq listing could reduce stock liquidity and subject it to 'penny stock' rules[246](index=246&type=chunk)[249](index=249&type=chunk) [Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates](index=66&type=section&id=Risks%20Related%20to%20the%20Discovery%2C%20Development%20and%20Regulatory%20Approval%20of%20Our%20Product%20Candidates) Addresses risks in drug development, clinical trials, and regulatory approval processes - The company's CRAC channel inhibition science is novel and unproven, leading to unforeseen risks, difficulty in predicting development time/cost, and potential failure to result in approvable or marketable products[250](index=250&type=chunk)[251](index=251&type=chunk)[252](index=252&type=chunk) - Business success is highly dependent on Auxora, the lead product candidate, which may fail to achieve successful development or regulatory approval[253](index=253&type=chunk)[254](index=254&type=chunk)[255](index=255&type=chunk)[257](index=257&type=chunk) - Clinical development is lengthy, expensive, and uncertain; preclinical and early clinical trial results are not always predictive of future outcomes, and later-stage trials may fail[258](index=258&type=chunk)[259](index=259&type=chunk) - Delays in site initiation, patient enrollment, manufacturing, or other difficulties can significantly extend or terminate clinical trials[262](index=262&type=chunk)[264](index=264&type=chunk) - Preliminary, interim, and topline data from clinical trials are subject to change and audit, and may differ from final results, potentially harming business prospects[272](index=272&type=chunk)[273](index=273&type=chunk) - Serious adverse events (SAEs), undesirable side effects, or unexpected properties of product candidates could lead to discontinuation of development, refusal of regulatory approval, or market withdrawal[274](index=274&type=chunk)[276](index=276&type=chunk)[278](index=278&type=chunk)[279](index=279&type=chunk)[280](index=280&type=chunk) - Special designations (e.g., Fast Track, Breakthrough Therapy, Orphan Drug) may be sought to expedite approvals but are not guaranteed and may not ultimately benefit the development process[281](index=281&type=chunk)[285](index=285&type=chunk)[286](index=286&type=chunk)[287](index=287&type=chunk)[288](index=288&type=chunk)[291](index=291&type=chunk)[292](index=292&type=chunk) - Product candidates must meet extensive regulatory requirements, and any approval may come with limitations, conditions, or require substantial additional development expenses[296](index=296&type=chunk)[298](index=298&type=chunk)[299](index=299&type=chunk)[300](index=300&type=chunk)[301](index=301&type=chunk) - Failure to obtain FDA approval for proposed product names, including Auxora, could adversely affect branding and commercialization[302](index=302&type=chunk)[304](index=304&type=chunk) - Ongoing regulatory obligations post-approval, including compliance with cGMP and post-marketing studies, may result in significant additional expense and potential penalties for non-compliance[305](index=305&type=chunk)[306](index=306&type=chunk)[307](index=307&type=chunk)[308](index=308&type=chunk)[309](index=309&type=chunk) - Improper promotion of off-label uses of approved products could lead to significant liability, fines, and restrictions[310](index=310&type=chunk)[312](index=312&type=chunk) - Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could delay product development and approval[313](index=313&type=chunk)[314](index=314&type=chunk) - Failure to identify or discover other product candidates or capitalize on the proprietary platform could limit commercial opportunities[315](index=315&type=chunk)[316](index=316&type=chunk)[317](index=317&type=chunk) [Risks Related to Manufacturing, Commercialization and Reliance on Third Parties](index=88&type=section&id=Risks%20Related%20to%20Manufacturing%2C%20Commercialization%20and%20Reliance%20on%20Third%20Parties) Covers risks from third-party reliance, manufacturing, market acceptance, and reimbursement - The company relies heavily on third parties (CROs, clinical investigators) for research, preclinical studies, and clinical trials, and their failure to perform satisfactorily could delay development programs or increase costs[321](index=321&type=chunk)[322](index=322&type=chunk)[325](index=325&type=chunk)[326](index=326&type=chunk)[327](index=327&type=chunk) - Reliance on third-party manufacturers for product candidates carries risks of limited or interrupted supply, unsatisfactory quality, and non-compliance with cGMP regulations, potentially delaying development or commercialization[328](index=328&type=chunk)[329](index=329&type=chunk)[330](index=330&type=chunk)[331](index=331&type=chunk)[332](index=332&type=chunk) - Approved product candidates may fail to achieve sufficient market acceptance by physicians, patients, hospitals, and healthcare payors, limiting commercial success[333](index=333&type=chunk)[335](index=335&type=chunk) - Unfavorable pricing regulations or third-party coverage and reimbursement policies could make it difficult to sell product candidates profitably, as patients rely on payors to cover costs[336](index=336&type=chunk)[337](index=337&type=chunk)[338](index=338&type=chunk)[339](index=339&type=chunk)[340](index=340&type=chunk)[341](index=341&type=chunk)[342](index=342&type=chunk)[343](index=343&type=chunk) - Inability to establish internal sales and marketing capabilities or secure agreements with third parties for these functions would hinder successful commercialization of approved product candidates[344](index=344&type=chunk)[345](index=345&type=chunk)[346](index=346&type=chunk) - Failure to obtain regulatory approval or commercialize product candidates outside the United States would limit their full market potential[347](index=347&type=chunk) [Risks Related to Our Industry and Business Operations](index=97&type=section&id=Risks%20Related%20to%20Our%20Industry%20and%20Business%20Operations) Examines risks concerning personnel, competition, data protection, and healthcare regulations - The company is highly dependent on key personnel, and failure to attract and retain qualified individuals could impede development and commercialization efforts[348](index=348&type=chunk)[349](index=349&type=chunk)[350](index=350&type=chunk)[351](index=351&type=chunk) - The CEO and CBO also serve as managing directors for Valence, a significant stockholder, potentially leading to conflicts of interest or diversion of attention[352](index=352&type=chunk) - Expected expansion of development, regulatory, and operational capabilities may lead to difficulties in managing growth, potentially disrupting operations[353](index=353&type=chunk)[354](index=354&type=chunk)[355](index=355&type=chunk)[356](index=356&type=chunk) - The company faces substantial competition from larger, more resourced companies, as well as smaller entities, which could result in competitors developing or commercializing products more quickly or successfully[357](index=357&type=chunk)[358](index=358&type=chunk)[359](index=359&type=chunk)[360](index=360&type=chunk)[361](index=361&type=chunk)[363](index=363&type=chunk) - Future collaboration arrangements may not be successful, potentially altering or delaying development and commercialization plans[364](index=364&type=chunk)[365](index=365&type=chunk)[366](index=366&type=chunk) - Failure to comply with applicable data protection laws (e.g., CCPA, GDPR, DPDP) could lead to government enforcement actions, private litigation, and adverse publicity, negatively affecting operating results[367](index=367&type=chunk)[368](index=368&type=chunk)[369](index=369&type=chunk)[370](index=370&type=chunk)[371](index=371&type=chunk)[372](index=372&type=chunk)[373](index=373&type=chunk)[374](index=374&type=chunk) - Information technology systems, or those of third parties, may suffer security breaches or disruptions, compromising confidential information, delaying development, and exposing the company to liability[375](index=375&type=chunk)[376](index=376&type=chunk)[377](index=377&type=chunk)[378](index=378&type=chunk)[379](index=379&type=chunk)[380](index=380&type=chunk) - Adverse effects from natural disasters, terrorism, or unforeseen events could disrupt business continuity, especially given reliance on single-site operations and lack of comprehensive disaster recovery plans[381](index=381&type=chunk) - The ability to utilize net operating loss (NOL) carryforwards and other tax attributes may be limited due to ownership changes or changes in tax laws, potentially increasing future tax liability[382](index=382&type=chunk)[383](index=383&type=chunk)[384](index=384&type=chunk) - Changes in healthcare laws and regulations (e.g., Affordable Care Act, IRA) and healthcare policy could significantly impact the business, affecting marketing approval, post-approval activities, and profitability[385](index=385&type=chunk)[386](index=386&type=chunk)[387](index=387&type=chunk)[388](index=388&type=chunk)[389](index=389&type=chunk)[390](index=390&type=chunk)[391](index=391&type=chunk)[392](index=392&type=chunk)[393](index=393&type=chunk) - Non-compliance with fraud and abuse, transparency, government price reporting, and other healthcare laws could lead to substantial penalties, exclusion from government programs, and reputational harm[394](index=394&type=chunk)[396](index=396&type=chunk)[397](index=397&type=chunk)[398](index=398&type=chunk)[399](index=399&type=chunk)[400](index=400&type=chunk) - Misconduct by employees, principal investigators, consultants, or commercial partners, including non-compliance with regulatory standards or insider trading, could result in significant penalties and harm to reputation[401](index=401&type=chunk) [Risks Related to Our Intellectual Property](index=115&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) Details risks concerning patent protection, intellectual property infringement, and trade secret confidentiality - Inability to obtain and maintain sufficient intellectual property protection for Auxora and other proprietary technologies could allow competitors to commercialize similar products, adversely affecting the business[402](index=402&type=chunk)[403](index=403&type=chunk)[404](index=404&type=chunk)[405](index=405&type=chunk)[406](index=406&type=chunk)[407](index=407&type=chunk)[408](index=408&type=chunk)[409](index=409&type=chunk)[410](index=410&type=chunk)[411](index=411&type=chunk) - Patent terms may be inadequate to protect competitive position for product candidates for a sufficient duration, leading to competition from generic products upon expiration[414](index=414&type=chunk)[416](index=416&type=chunk) - Failure to obtain patent term extension for Auxora could materially harm the business by reducing the period of exclusive market rights[415](index=415&type=chunk)[418](index=418&type=chunk) - Non-compliance with procedural, document submission, and fee payment requirements by governmental patent agencies could lead to reduced or eliminated patent protection[419](index=419&type=chunk) - Changes in U.S. patent law, including recent Supreme Court decisions and the America Invents Act, could diminish the value of patents and impair the ability to protect Auxora[420](index=420&type=chunk)[421](index=421&type=chunk)[422](index=422&type=chunk) - Inability to protect intellectual property rights globally, due to varying national laws and enforcement, could allow third parties to practice inventions in countries without patent protection[423](index=423&type=chunk)[424](index=424&type=chunk)[425](index=425&type=chunk)[426](index=426&type=chunk)[427](index=427&type=chunk) - Claims challenging inventorship or ownership of patents and other intellectual property could lead to loss of valuable rights, monetary damages, and substantial litigation costs[428](index=428&type=chunk) - Failure to obtain or maintain necessary rights to product components and processes through acquisitions and in-licenses could hinder business growth and commercialization[429](index=429&type=chunk)[430](index=430&type=chunk)[431](index=431&type=chunk)[432](index=432&type=chunk)[433](index=433&type=chunk) - Third-party claims alleging intellectual property infringement may prevent or delay drug discovery and development efforts, leading to costly litigation, damages, or the need for licenses[434](index=434&type=chunk)[435](index=435&type=chunk)[436](index=436&type=chunk)[437](index=437&type=chunk)[438](index=438&type=chunk)[439](index=439&type=chunk)[440](index=440&type=chunk)[441](index=441&type=chunk)[442](index=442&type=chunk)[443](index=443&type=chunk)[444](index=444&type=chunk)[445](index=445&type=chunk)[446](index=446&type=chunk)[447](index=447&type=chunk) - Claims of wrongful hiring or use/disclosure of confidential information/trade secrets from former employers could lead to litigation, loss of intellectual property rights, or personnel[448](index=448&type=chunk) - Lawsuits to protect or enforce patents can be expensive, time-consuming, and unsuccessful, potentially leading to invalidation of patents or substantial costs[450](index=450&type=chunk)[451](index=451&type=chunk)[452](index=452&type=chunk)[453](index=453&type=chunk)[454](index=454&type=chunk)[455](index=455&type=chunk) - Inability to protect the confidentiality of trade secrets, especially when shared with third parties, could harm the business and competitive position[456](index=456&type=chunk)[457](index=457&type=chunk)[458](index=458&type=chunk) - Inadequate protection of trademarks and trade names could prevent building name recognition and adversely affect the business[459](index=459&type=chunk)[460](index=460&type=chunk)[461](index=461&type=chunk) - Future collaboration arrangements may not be successful, depending heavily on collaborators' efforts and potentially leading to relinquishing control or costly disputes[462](index=462&type=chunk)[463](index=463&type=chunk) [General Risk Factors](index=133&type=section&id=General%20Risk%20Factors) Covers broad risks including litigation, compliance, stock volatility, and corporate governance - Business operations may lead to disputes, claims, and lawsuits, which can be costly, time-consuming, and adversely impact financial position and results of operations[462](index=462&type=chunk)[464](index=464&type=chunk)[465](index=465&type=chunk) - Failure to comply with environmental, health, and safety laws and regulations could result in fines, penalties, or substantial costs[466](index=466&type=chunk)[467](index=467&type=chunk)[468](index=468&type=chunk)[469](index=469&type=chunk)[470](index=470&type=chunk)[471](index=471&type=chunk) - Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and affect reported results of operations[472](index=472&type=chunk) - The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws, with violations leading to serious consequences[473](index=473&type=chunk)[475](index=475&type=chunk) - The market price of the company's stock has been and may continue to be volatile due to various factors, potentially leading to loss of investment[476](index=476&type=chunk)[477](index=477&type=chunk)[478](index=478&type=chunk) - Financial reporting obligations as a public company are expensive and time-consuming, requiring substantial management time for compliance[479](index=479&type=chunk) - The management team's relative lack of public company experience may put the company at a competitive disadvantage in complying with legal and regulatory requirements[480](index=480&type=chunk) - Substantial future sales of common stock by existing stockholders could adversely affect the market price[481](index=481&type=chunk)[482](index=482&type=chunk) - Principal stockholders and management own a significant percentage of stock, allowing them to exert significant control over matters subject to stockholder approval, potentially conflicting with other stockholders' interests[483](index=483&type=chunk) - As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors or limit the ability to raise additional funds[484](index=484&type=chunk) - The company does not anticipate paying cash dividends, making capital appreciation the sole source of gain for investors[485](index=485&type=chunk) - If equity research analysts do not publish research or publish unfavorable reports, the stock price and trading volume could decline[486](index=486&type=chunk) - Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult and prevent stockholders from replacing management[487](index=487&type=chunk) - Bylaws designating Delaware courts as the exclusive forum for disputes could limit stockholders' ability to choose a favorable judicial forum[488](index=488&type=chunk)[490](index=490&type=chunk) - Unfavorable global economic conditions could adversely affect business, financial condition, or results of operations[491](index=491&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=143&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Reports no unregistered sales of equity securities or use of proceeds for the period - No unregistered sales of equity securities or use of proceeds were reported[492](index=492&type=chunk) [Item 3. Defaults Upon Senior Securities](index=143&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported - No defaults upon senior securities were reported[493](index=493&type=chunk) [Item 4. Mine Safety Disclosures](index=143&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Confirms that mine safety disclosures are not applicable to the company - Mine safety disclosures are not applicable to CalciMedica, Inc[494](index=494&type=chunk) [Item 5. Other Information](index=143&type=section&id=Item%205.%20Other%20Information) Indicates that no other information was reported - No other information was reported[495](index=495&type=chunk) [Item 6. Exhibits](index=144&type=section&id=Item%206.%20Exhibits) Lists all exhibits filed as part of the Quarterly Report on Form 10-Q - The exhibits include the **Amended and Restated Certificate of Incorporation**, **Restated Bylaws**, various forms of **Registration Rights Agreements**, and **Warrants to Purchase Common Stock**[497](index=497&type=chunk)[498](index=498&type=chunk) - Certifications from the **Principal Executive Officer** and **Principal Financial Officer**, pursuant to Rules 13a-14(a) and 15d-14(a) and 18 U.S.C. Section 1350, are included[498](index=498&type=chunk) - Inline XBRL Instance Document, Taxonomy Extension Schema, and Cover Page Interactive Data File are also part of the exhibits[498](index=498&type=chunk) [SIGNATURES](index=147&type=section&id=SIGNATURES) Contains the required signatures of the registrant's authorized officers - The report is signed by A. Rachel Leheny, Ph.D., Chief Executive Officer, and Daniel Geffken, Interim Chief Financial Officer, on May 13, 2024[503](index=503&type=chunk)